Synonym
S-Y048; SY048; S Y048;
IUPAC/Chemical Name
(S)-5-(5-chloro-2-(6-(3-chlorophenyl)hexyl)-1-methyl-1H-indol-3-yl)-3-methyl-5-oxopentanoic acid
InChi Key
XGNFPJZMWOIDAH-SFHVURJKSA-N
InChi Code
InChI=1S/C27H31Cl2NO3/c1-18(15-26(32)33)14-25(31)27-22-17-21(29)12-13-23(22)30(2)24(27)11-6-4-3-5-8-19-9-7-10-20(28)16-19/h7,9-10,12-13,16-18H,3-6,8,11,14-15H2,1-2H3,(H,32,33)/t18-/m0/s1
SMILES Code
O=C(O)C[C@@H](C)CC(C1=C(CCCCCCC2=CC=CC(Cl)=C2)N(C)C3=C1C=C(Cl)C=C3)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
488.45
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cossette C, Chourey S, Ye Q, Reddy CN, Wang R, Poulet S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS. Metabolism of anti-inflammatory OXE (oxoeicosanoid) receptor antagonists by nonhuman primates. Eur J Pharm Sci. 2022 May 1;172:106144. doi: 10.1016/j.ejps.2022.106144. Epub 2022 Feb 11. PMID: 35158054.
2: Cossette C, Miller LA, Ye Q, Chourey S, Reddy CN, Rokach J, Powell WS. Targeting the OXE receptor with a selective antagonist inhibits allergen-induced pulmonary inflammation in non-human primates. Br J Pharmacol. 2022 Jan;179(2):322-336. doi: 10.1111/bph.15721. Epub 2021 Dec 16. PMID: 34766334; PMCID: PMC8793878.
3: Powell WS, Rokach J. Targeting the OXE receptor as a potential novel therapy for asthma. Biochem Pharmacol. 2020 Sep;179:113930. doi: 10.1016/j.bcp.2020.113930. Epub 2020 Mar 30. PMID: 32240653.
4: Ye Q, Chourey S, Reddy CN, Wang R, Cossette C, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS. Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys. Br J Pharmacol. 2020 Jan;177(2):388-401. doi: 10.1111/bph.14874. Epub 2020 Jan 17. PMID: 31655025; PMCID: PMC6989946.
5: Miller LA, Cossette C, Chourey S, Ye Q, Reddy CN, Rokach J, Powell WS. Inhibition of allergen-induced dermal eosinophilia by an oxoeicosanoid receptor antagonist in non-human primates. Br J Pharmacol. 2020 Jan;177(2):360-371. doi: 10.1111/bph.14872. Epub 2020 Jan 17. PMID: 31655023; PMCID: PMC6989951.
